aspirin
AssetAlso BAYE4465, BAY1019036, BAYE004465, UI1610477
Irreversibly inhibits cyclooxygenase-1 and 2, decreasing prostaglandin and thromboxane synthesis
- Stage
- Approved
- Modality
- Small molecule
- Target
- Lipid and ceramide metabolism
- 24
- Indications
- 568
- Trials
- 5
- Developers
Indications
25No named disease
Approved, accessdata.fda.gov, 7 Oct 2026
Acute coronary syndrome
Phase 3, Completed, NCT00910065, clinicaltrials.gov, 7 Oct 2026
Blood viscosity
Phase 3, Completed, NCT05730621, clinicaltrials.gov, 7 Oct 2026
22 more
In the full profile
- Targets and what it contains5
- Owner and partners5
- Trials568
- Evidence for its targets5
- Competitors12
- Aging relevance3
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026, 34 sources